Evidence map›Paper›PMID 42266370›Full record

ArticleFrontiers in pharmacology2026

Evaluating Cordyceps militaris capsules on post-bronchodilator FEV

Siqi Lin, Tianming Liao, Feiting Fan, Yuanbin Chen, Yue Yan, Hangming Dong, Shaofeng Zhan, Yuanbing Zhang, Kun Xiao, Lin Lin and 1 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Siqi Lin *State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
Tianming Liao *State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
Feiting FanState Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
Yuanbin ChenState Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
Yue YanChina-Japan Friendship Hospital, Beijing, China.
Hangming DongNanfang Hospital Southern Medical University, Guangzhou, China.
Shaofeng ZhanThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Yuanbing ZhangJiangxi Provincial Hospital of Chinese Medicine, Nanchang, China.
Kun XiaoThe Second People's Hospital of Baiyun and Guangzhou, Guangzhou, China.
Lin LinState Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
Lei WuState Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chronic Obstructive Pulmonary Disease (COPD) is characterized by a progressive deterioration of lung function, which occurs at its fastest rate in the early stages (GOLD I-II). Preliminary clinical investigation has suggested that Methods: This study is a multi-center, randomized, double-blind, placebo-controlled clinical trial involving 160 eligible patients aged between 40 and 85 years. After a 1-week run-in period, participants are randomized in a 1:1 ratio to receive either Discussion: This study is designed to evaluate the therapeutic potential of Clinical Trial Registration: https://www.chictr.org.cn/, ChiCTR2400086743, identifier, ChiCTR2400086743.

Indexed as

chronic obstructive pulmonary diseaseCordyceps militaris capsuleslung functionpost-bronchodilator FEV1protocol

Identifiers

PMID42266370
PMCPMC13243416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.